1. bookVolume 12 (2018): Edizione 6 (December 2018)
Dettagli della rivista
License
Formato
Rivista
eISSN
1875-855X
Prima pubblicazione
01 Jun 2007
Frequenza di pubblicazione
6 volte all'anno
Lingue
Inglese
Accesso libero

Proportion of vulvar premalignant and malignant lesions in overall vulvar specimens in Thailand

Pubblicato online: 24 Oct 2019
Volume & Edizione: Volume 12 (2018) - Edizione 6 (December 2018)
Pagine: 281 - 286
Dettagli della rivista
License
Formato
Rivista
eISSN
1875-855X
Prima pubblicazione
01 Jun 2007
Frequenza di pubblicazione
6 volte all'anno
Lingue
Inglese

Vulvar lesion is one of the common gynecologic problems. It can be categorized into three groups, which are benign, premalignant, and malignant lesion. The general appearance is varying in size, character, and color. The squamous cell carcinoma mostly present as a mass or chronic ulcer, which is frequently assumed to be a benign lesion [1]. The vulvar intraepithelial neoplasia (VIN) could be presented as maculopapular lesion that has many different colors such as white, pink, red, or even dark brown. The malignant melanoma is typically a hyperpigmented lesion but can also be seen as a hypopigmented lesion [2]. Therefore, it is difficult to diagnose the lesion without the pathological result.

Vulvar cancer constitutes 3%–8% of all female genital malignancies [3, 4]. About 27,000 women worldwide are

diagnosed with vulvar cancer each year [3]. It has been estimated that vulvar cancer occurs in 2.5 per 100,000 women-years in developed countries. However, it is two to three times more frequent in the developing countries. An increasing incidence of VIN and vulvar cancer has been reported in the past decade. The possible explanation including increasing rate of human papilloma virus (HPV) infection due to an early onset of intercourse and a higher participation in early diagnostic measurement [4]. The incidence of vulvar cancer begins to increase quickly after the age of 50 years [5]. VIN and vulvar cancers need more concerns and may become an important problem in the future with regard to the trend of increasing aging population.

There are very limited data of pathological diagnosis and clinicopathologic features of vulvar lesion in Thailand. Only three reports have been published, and they focused only on the cancerous lesion [6, 7, 8]. The primary objective of this study was to assess the proportion of vulvar premalignant and malignant lesions in overall vulvar specimens at King Chulalongkorn Memorial Hospital (KCMH), a tertiary-care hospital and medical school, during a period of 14 years. Secondary objective was to evaluate the clinicopathologic features of each vulvar lesion.

Materials and methods

Retrospective descriptive study was conducted after approval from the Institutional Review Board, Faculty of Medicine, Chulalongkorn University (certificate of approval No. 305/2016). Pathologic reports of vulvar specimens from all patients who underwent vulvar-related operations between January 1, 2002 and December 31, 2015 at KCMH were retrieved from the database of Division of Gynecologic Pathology. Microscopic slides of all cases were reviewed by experienced gynecologic pathologist to confirm the diagnosis. Patients’ clinical characteristics including age, menopausal status, parity, lesion size, and lesion’s color were collected from the medical record. Cases with unavailable formalin-fixed paraffin blocks or medical records were excluded from the study.

Statistical analysis was performed using SPSS software version 17 (SPSS Inc., Chicago, IL, USA). The patients’ clinical characteristics and pathological data were compared by descriptive statistics including crude number, frequency, mean, and standard deviation. Pearson’s chi-squared test and unpaired T test were used to determine whether there is a statistical difference in categorical and continuous data, respectively. The univariate and multivariate logistic regression analysis were used to access for the odd ratio that the lesion would be premalignant or malignant lesion. All statistical tests were two sided, and P < 0.05 was considered significant.

Results

A total number of 700 patients were included in this study. About 114 patients were malignant (16.3%), 59 patients were premalignant (8.4%), and 527 patients were benign (75.3%). The pathological diagnosis distribution is shown in Table 1. Squamous cell carcinoma was the most common malignant vulvar lesion and accounted for nearly half of the malignant cases. The second and third most common malignant vulvar lesion is malignant melanoma and adenocarcinoma, respectively. In premalignant lesion, VIN1 and VIN3 were each diagnosed in approximately one-third of cases. Fibroepithelial polyp was the most common benign lesion (23.9%).

Diagnosis of vulvar lesion in number and percentage

Malignant (n = 114)Benign (n = 527)
Squamous cell55 (48.2)Fibroepithelial polyp126 (23.9)
carcinoma
Malignant melanoma12 (10.5)Epidermal inclusion cyst84 (15.9)
Adenocarcinoma10 (8.8)Inflammation72 (13.7)
Invasive Paget’s8 (7.0)Condyloma acumi-52 (9.9)
diseasenata
Soft tissue tumors7 (6.2)Seborrheic keratosis26 (4.9)
Verrucous carcinoma5 (4.4)Nevus22 (4.2)
Basal cell carcinoma4 (3.5)Hydradenoma17 (3.2)
papilliferum
Neuroendocrine4 (3.5)Lichen sclerosus15 (2.8)
tumors
Others9 (7.9)Hyperkeratosis12 (2.3)
Lipoma10 (1.9)
Premalignant (n = 59)Others91 (17.3)
VIN120 (33.9)
VIN319 (32.2)
Paget’s disease16 (27.1)
VIN24 (6.8)

Demographic data are listed in Table 2. Age of the patients ranged from 13 to 93 years with the mean age of 47.7 years. Mean age of the benign group was significantly lower than the premalignant and malignant groups. Almost 70% of the included populations were multiparous. Majority of the patient in the benign group were premenopause (65.7%), while in premalignant and malignant group, 64.7% were menopause women. The most presenting symptom in benign and malignant groups was palpable mass that was seen in less than half of the premalignant group.

Patient’s demographic characteristics

Demographic dataBenign (n = 527)Premalignant (n = 59)Malignant (n = 114)P*
Age (mean ± SD)45.1 ± 15.652.9 ± 14.556.9 ± 16.6<0.001**
Parity (%)
0192 (36.4)13 (22.1)21 (18.4)<0.001**
1159 (30.2)14 (23.7)17 (14.9)0.002**
2106 (20.1)16 (27.1)23 (20.2)0.494
>270 (13.3)16 (27.1)53 (46.5)<0.001**
Postmenopause (%)181 (34.3)38 (64.4)74 (64.9)<0.001**
Presenting symptom (%)
Mass425 (80.6)24 (40.7)86 (75.4)<0.001**
Rash73 (13.8)28 (47.5)24 (21.1)<0.001**
Itching29 (5.6)7 (11.8)4 (3.5)0.674

*Benign vs Premalignant and malignant.

**Statistical significance (P < 0.05).

Figure 1 represented the proportion of premalignant and malignant lesions in each age group. As the age increased, the proportion of premalignant and malignant lesions also increased. After the six decades, there was 42.4% chance that the lesion was premalignant or malignant.

Figure 1

Proportion of premalignant and malignant lesions in each age group.

Proportion of premalignant and malignant lesions based on the menopausal status was shown in Figure 2. There was higher percentage of premalignant and malignant lesions in the menopause group (38.2% vs 14.9%, P < 0.001).

Figure 2

Proportion of premalignant and malignant lesions in premenopause and menopause group.

Parity is also a significant factor associated with the malignancy risk. Increased parity raised the probability of vulvar lesion being premalignant or malignant lesion with the highest peak in women with five and more children (Figure 3).

Figure 3

Proportion of premalignant and malignant lesions in different parity.

Lesion characteristics were shown in Table 3. Half of the lesions located at the labia majora. The malignant lesion is most commonly submitted from the labia majora. The benign lesion was significantly smaller than the premalignant and malignant lesion (P < 0.001). Majority of the lesions showed unchanged skin color, which accounted for 62.4%.

Lesion characteristics

Demographic dataBenign (n = 527)Premalignant (n = 59)Malignant (n = 114)P*
Location (%)
Labia majora273 (51.9)37 (62.7)57 (50.0)0.240
Labia minora122 (23.1)10 (16.9)24 (21.1)0.523
Mon pubis47 (8.9)3 (5.1)9 (7.8)0.558
Anterior fourchette30 (5.7)6 (10.2)6 (5.3)0.365
Bartholin’s gland36 (6.8)0 (0)2 (1.8)0.015
Clitoris9 (1.7)2 (3.4)14 (12.2)<0.001**
Posterior fourchette10 (1.9)1 (1.7)2 (1.8)0.990
Size (cm) (%)
≤2 cm434 (82.4)21 (35.6)23 (20.2)<0.001**
>2–4 cm71 (13.5)24 (40.7)44 (38.6)<0.001**
>4 cm22 (4.1)14 (23.4)47 (41.2)<0.001**
Color (%)
Unchanged skin color364 (69.1)44 (74.6)29 (25.4)<0.001**
Hypopigment111 (21.1)8 (13.5)47 (41.2)0.004**
Erythematous26 (4.9)7 (11.9)28 (24.6)<0.001**
Hyperpigment26 (4.9)0 (0)10 (8.8)0.662

*Benign vs premalignant and malignant.

**Statistical significance (P < 0.05).

Based on the location, if the lesion was located at the clitoris, it was more likely to be premalignant or malignant condition. However, if the lesion is located at Bartholin’s gland, there was 94.7% chance that the lesion would be benign (Figure 4).

Figure 4

Proportion of premalignant and malignant lesions in each location.

Proportion of premalignant and malignant lesions in each size of lesion was shown in Figure 5. There was more percentage that the lesion would be a premalignant or malignant condition with the larger size of lesion. If the lesion was larger than 4 cm, the accumulate proportion of premalignant and malignant lesion was high as 73.4%.

Figure 5

Proportion of premalignant and malignant lesions in different lesion size.

Figure 6 demonstrated the proportion of vulvar premalignant and malignant lesion in different lesion colors. Approximately one-third of hyperpigmented and hypopigmented lesions were premalignant or malignant condition, while the percentage was increasing to more than half if the lesion was erythematous.

Figure 6

Proportion of premalignant and malignant lesions in different lesion colors.

The univariate and multivariate analyses were performed to determine the predicting factors of premalignant or malignant lesion (Table 4). In univariate analysis, there was statistical significance in old age, menopause, increased parity, large tumor size, lesion at clitoris, and erythematous lesion. Therefore, only four clinical factors remained significantly associated with malignancy risk by multivariate analysis. These four factors were increased parity (odds ratio [OR] 1.19, P = 0.010), large tumor size (OR 2.00, P < 0.001), lesion at clitoris (OR 16.67, P = 0.002), and erythematous lesion (OR 2.41, P = 0.026).

Univariate and multivariate analysis to predict vulvar malignancy risk

FactorsUnivariate analysisMultivariate analysis
OR95% CIPOR95% CIP
Age (years)1.041.03–1.05<0.001*1.000.97–1.020.890
Menopause (yes, no)3.512.45–5.03<0.001*1.830.83–4.050.130
Parity (times)1.411.28–1.56<0.001*1.191.04–1.360.010*
Size (cm)2.101.84–2.40<0.001*2.001.73–2.31<0.001*
Location
Labia majora6.191.46–26.230.013*3.260.72–14.70.130
Labia minora5.021.14–21.890.032*4.200.91–19.60.070
Clitoris32.006.19–165.2<0.001*15.672.72–90.90.002*
Color
Hyperpigment1.920.89–4.150.0982.380.94–6.060.068
Hypopigment2.471.64–3.72<0.001*1.140.68–1.910.625
Erythematous6.713.81–11.83<0.001*2.411.11–5.240.026*

*Statistical significance (P < 0.05).

CI, confidence interval; OR, odds ratio.

When divided into two 7-year periods, 2002–2008 and 2009–2015, there was increased in the incidence of both premalignant and malignant vulvar lesions, but statistical significance was demonstrated in only malignant group (Table 5).

Trends of vulvar premalignant and malignant lesions

Year 2002–2008 (n = 342)Year 2009–2015 (n = 358)P
Malignant vulvar lesion45 (13.2%)69 (19.3%)0.028*
Premalignant vulvar lesion25 (7.3%)34 (9.5%)0.298

*Statistical significance (P < 0.05).

As focusing on the women younger than 60 years; although the incidence of vulvar malignancy was increasing from 9.6% in 2002–2008 to 14.5% in 2009–2015, but there was no statistical significance (P = 0.083).

Discussion

Vulvar cancer is a rare disease and should be considered as a quietly progressive problem. The increased incidence has been reported in several countries such as Australia, England, Netherland, and Germany; especially in women younger than 60–70 years [4, 9, 10, 11]. Barlow et al. reported a significant 84% increase in incidence of vulvar cancer in women younger than 60 years with no change for women more than 60 years [9]. Trends of incidence of premalignant vulva lesion was also increased. It has been reported that vulvar carcinoma in situ increased 411% from 1973 to 2000 [5]. Invasive vulvar cancer increased 20% during the same period [5]. The present study of 14-year period showed that the authors also found the increased incidence of both premalignant and malignant vulvar lesions, but statistical significance was demonstrated in only malignant group. Vulvar malignancy was significantly increased 6.1% from 2002–2008 to 2009–2015. However, there was not significantly increased incidence of vulvar cancer in the women younger than 60 years.

The present study was the largest one that recruited up to 114 cases of vulvar cancer, compared to other previous studies that was ranging from 26 to 69 cases [6, 7, 8]. The most common malignant vulvar lesion was squamous cell carcinoma, same as other studies. However, the proportion of squamous cell carcinoma was only 48.2%, which was much lower than previous studies (76%–89%) [1, 2, 4, 5, 6, 7, 8]. This finding may be explained by the higher possibility to submit more different rare types of vulvar lesions than other hospital because KCMH is a tertiary referral center.

Based on the univariate and multivariate analyses, increased parity, large tumor size, clitoris-located lesion, and erythematous lesion were associated with increasing malignancy risk. One hypothesis of the pathogenesis of vulvar cancer is the exposure to the HPV [12]. Multiparous women seem to have higher risk of HPV infection and may associated with increased chance of developing vulvar cancer. Interestingly, lesion at the clitoris was associated with increased malignancy risk. This finding may be explained by the anatomy of the clitoris. The clitoris is located at the crevices between labia minora and is not easily seen or palpated. Small benign lesion may quietly regress without any symptom. The lesions that can be detected by the woman herself generally progress for a while, which are more commonly seen in the malignancy than in the benign condition.

Seven hundred cases of vulvar lesions in a 14-year period were reviewed, focusing on the pathological diagnosis and clinicopathologic features. Therefore, it had few limitations as it was a retrospective study. Biopsy or operation was not performed in every patient. Moreover, the operation was tended to be withheld in cases with benign-looking lesion. However, these data are still useful for patient counseling and can be used as the baseline data for further researches of the vulvar lesion.

Conclusion

The proportion of malignant and premalignant lesions in overall vulvar specimens was 16.3% and 8.4%, respectively. Increased parity, large tumor size, clitoris-located lesion, and erythematous lesion were associated with increasing malignancy risk.

Figure 1

Proportion of premalignant and malignant lesions in each age group.
Proportion of premalignant and malignant lesions in each age group.

Figure 2

Proportion of premalignant and malignant lesions in premenopause and menopause group.
Proportion of premalignant and malignant lesions in premenopause and menopause group.

Figure 3

Proportion of premalignant and malignant lesions in different parity.
Proportion of premalignant and malignant lesions in different parity.

Figure 4

Proportion of premalignant and malignant lesions in each location.
Proportion of premalignant and malignant lesions in each location.

Figure 5

Proportion of premalignant and malignant lesions in different lesion size.
Proportion of premalignant and malignant lesions in different lesion size.

Figure 6

Proportion of premalignant and malignant lesions in different lesion colors.
Proportion of premalignant and malignant lesions in different lesion colors.

Patient’s demographic characteristics

Demographic dataBenign (n = 527)Premalignant (n = 59)Malignant (n = 114)P*
Age (mean ± SD)45.1 ± 15.652.9 ± 14.556.9 ± 16.6<0.001**
Parity (%)
0192 (36.4)13 (22.1)21 (18.4)<0.001**
1159 (30.2)14 (23.7)17 (14.9)0.002**
2106 (20.1)16 (27.1)23 (20.2)0.494
>270 (13.3)16 (27.1)53 (46.5)<0.001**
Postmenopause (%)181 (34.3)38 (64.4)74 (64.9)<0.001**
Presenting symptom (%)
Mass425 (80.6)24 (40.7)86 (75.4)<0.001**
Rash73 (13.8)28 (47.5)24 (21.1)<0.001**
Itching29 (5.6)7 (11.8)4 (3.5)0.674

Lesion characteristics

Demographic dataBenign (n = 527)Premalignant (n = 59)Malignant (n = 114)P*
Location (%)
Labia majora273 (51.9)37 (62.7)57 (50.0)0.240
Labia minora122 (23.1)10 (16.9)24 (21.1)0.523
Mon pubis47 (8.9)3 (5.1)9 (7.8)0.558
Anterior fourchette30 (5.7)6 (10.2)6 (5.3)0.365
Bartholin’s gland36 (6.8)0 (0)2 (1.8)0.015
Clitoris9 (1.7)2 (3.4)14 (12.2)<0.001**
Posterior fourchette10 (1.9)1 (1.7)2 (1.8)0.990
Size (cm) (%)
≤2 cm434 (82.4)21 (35.6)23 (20.2)<0.001**
>2–4 cm71 (13.5)24 (40.7)44 (38.6)<0.001**
>4 cm22 (4.1)14 (23.4)47 (41.2)<0.001**
Color (%)
Unchanged skin color364 (69.1)44 (74.6)29 (25.4)<0.001**
Hypopigment111 (21.1)8 (13.5)47 (41.2)0.004**
Erythematous26 (4.9)7 (11.9)28 (24.6)<0.001**
Hyperpigment26 (4.9)0 (0)10 (8.8)0.662

Univariate and multivariate analysis to predict vulvar malignancy risk

FactorsUnivariate analysisMultivariate analysis
OR95% CIPOR95% CIP
Age (years)1.041.03–1.05<0.001*1.000.97–1.020.890
Menopause (yes, no)3.512.45–5.03<0.001*1.830.83–4.050.130
Parity (times)1.411.28–1.56<0.001*1.191.04–1.360.010*
Size (cm)2.101.84–2.40<0.001*2.001.73–2.31<0.001*
Location
Labia majora6.191.46–26.230.013*3.260.72–14.70.130
Labia minora5.021.14–21.890.032*4.200.91–19.60.070
Clitoris32.006.19–165.2<0.001*15.672.72–90.90.002*
Color
Hyperpigment1.920.89–4.150.0982.380.94–6.060.068
Hypopigment2.471.64–3.72<0.001*1.140.68–1.910.625
Erythematous6.713.81–11.83<0.001*2.411.11–5.240.026*

Trends of vulvar premalignant and malignant lesions

Year 2002–2008 (n = 342)Year 2009–2015 (n = 358)P
Malignant vulvar lesion45 (13.2%)69 (19.3%)0.028*
Premalignant vulvar lesion25 (7.3%)34 (9.5%)0.298

Diagnosis of vulvar lesion in number and percentage

Malignant (n = 114)Benign (n = 527)
Squamous cell55 (48.2)Fibroepithelial polyp126 (23.9)
carcinoma
Malignant melanoma12 (10.5)Epidermal inclusion cyst84 (15.9)
Adenocarcinoma10 (8.8)Inflammation72 (13.7)
Invasive Paget’s8 (7.0)Condyloma acumi-52 (9.9)
diseasenata
Soft tissue tumors7 (6.2)Seborrheic keratosis26 (4.9)
Verrucous carcinoma5 (4.4)Nevus22 (4.2)
Basal cell carcinoma4 (3.5)Hydradenoma17 (3.2)
papilliferum
Neuroendocrine4 (3.5)Lichen sclerosus15 (2.8)
tumors
Others9 (7.9)Hyperkeratosis12 (2.3)
Lipoma10 (1.9)
Premalignant (n = 59)Others91 (17.3)
VIN120 (33.9)
VIN319 (32.2)
Paget’s disease16 (27.1)
VIN24 (6.8)

Léonard B, Kridelka F, Delbecque K, Goffin F, Demoulin S, Doyen J, et al. A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma. Biomed Res Int. 2014; 201:480–573.LéonardBKridelkaFDelbecqueKGoffinFDemoulinSDoyenJet alA clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinomaBiomed Res Int201420148057310.1155/2014/480573395628924719870Search in Google Scholar

Tcheung WJ, Selim MA, Herndon JE 2nd, Abernethy AP, Nelson KC. Clinicopathologic study of 85 cases of melanoma of the female genitalia. J Am Acad Dermatol. 2012; 67:598–605.TcheungWJSelimMAHerndonJE2ndAbernethyAPNelsonKCClinicopathologic study of 85 cases of melanoma of the female genitaliaJ Am Acad Dermatol20126759860510.1016/j.jaad.2011.11.92122243767Search in Google Scholar

Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006; 20:207–25.SankaranarayananRFerlayJWorldwide burden of gynaecological cancer: the size of the problemBest Pract Res Clin Obstet Gynaecol2006202072510.1016/j.bpobgyn.2005.10.00716359925Search in Google Scholar

Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D. Epidemiology of vulvar and vaginal cancer in Germany. Arch Gyne col Obstet. 2011; 284:169–74.DittmerCKatalinicAMundhenkeCThillMFischerDEpidemiology of vulvar and vaginal cancer in GermanyArch Gyne col Obstet20112841697410.1007/s00404-011-1850-921340687Search in Google Scholar

Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006; 107:1018–22.JudsonPLHabermannEBBaxterNNDurhamSBVirnigBATrends in the incidence of invasive and in situ vulvar carcinomaObstet Gynecol200610710182210.1097/01.AOG.0000210268.57527.a116648405Search in Google Scholar

Hanprasertpong J, Chichareon S, Wootipoom V, Buhachat R, Tocharoenvanich S, Geater A. Clinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 cases. J Med Assoc Thai. 2005; 88:575–81.HanprasertpongJChichareonSWootipoomVBuhachatRTocharoenvanichSGeaterAClinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 casesJ Med Assoc Thai20058857581Search in Google Scholar

Pengsaa P, Pothinam S, Udomthavornsuk B. Vulvar carcinoma at Srinagarind Hospital, Khon Kaen, Thailand. Eur J Gynaecol Oncol. 1993; 14:56–62.PengsaaPPothinamSUdomthavornsukBVulvar carcinoma at Srinagarind Hospital, Khon Kaen, ThailandEur J Gynaecol Oncol1993145662Search in Google Scholar

Manchana T, Sirisubya N, Lertkhachonsuk R, Sittisomwong T, Vasuratna A, Termrungruanglert W, et al. Vulvar carcinoma at King Chulalongkorn Memorial Hospital between 1994–2003. Chula Med J. 2004; 48:91–9.ManchanaTSirisubyaNLertkhachonsukRSittisomwongTVasuratnaATermrungruanglertWet alVulvar carcinoma at King Chulalongkorn Memorial Hospital between 1994–2003Chula Med J200448919Search in Google Scholar

Barlow EL, Kang YJ, Hacker NF, Canfell K. Changing trends in vulvar cancer incidence and mortality rates in Australia since 1982. Int J Gynecol Cancer. 2015; 25:1683–9.BarlowELKangYJHackerNFCanfellKChanging trends in vulvar cancer incidence and mortality rates in Australia since 1982Int J Gynecol Cancer2015251683910.1097/IGC.000000000000054726495761Search in Google Scholar

Lai J, Elleray R, Nordin A, Hirschowitz L, Rous B, Gildea C, et al. Vulvar cancer incidence, mortality and survival in England: age-related trends. BJOG. 2014; 121:728–38LaiJEllerayRNordinAHirschowitzLRousBGildeaCet alVulvar cancer incidence, mortality and survival in England: age-related trendsBJOG20141217283810.1111/1471-0528.1245924148762Search in Google Scholar

Schuurman MS, van den Einden LC, Massuger LF, Kiemeney LA, van der Aa MA, de Hullu JA. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. Eur J Cancer. 2013; 49:3872–80.SchuurmanMSvan den EindenLCMassugerLFKiemeneyLAvan der AaMAde HulluJATrends in incidence and survival of Dutch women with vulvar squamous cell carcinomaEur J Cancer20134938728010.1016/j.ejca.2013.08.00324011936Search in Google Scholar

Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human papillomavirus-associated cancers-United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2016; 65:661–6.ViensLJHenleySJWatsonMMarkowitzLEThomasCCThompsonTDet alHuman papillomavirus-associated cancers-United States, 2008-2012MMWR Morb Mortal Wkly Rep201665661610.15585/mmwr.mm6526a127387669Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo